Polycythemia Vera - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Polycythemia Vera - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Polycythemia Vera - Pipeline Review, H2 2016', provides an overview of the Polycythemia Vera pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera
- The report reviews pipeline therapeutics for Polycythemia Vera by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Polycythemia Vera therapeutics and enlists all their major and minor projects
- The report assesses Polycythemia Vera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Polycythemia Vera

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Polycythemia Vera
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Polycythemia Vera pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Polycythemia Vera Overview 7
Therapeutics Development 8
Pipeline Products for Polycythemia Vera - Overview 8
Polycythemia Vera - Therapeutics under Development by Companies 9
Polycythemia Vera - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Polycythemia Vera - Products under Development by Companies 13
Polycythemia Vera - Companies Involved in Therapeutics Development 14
ANP Technologies, Inc. 14
Bristol-Myers Squibb Company 15
F. Hoffmann-La Roche Ltd. 16
Galena Biopharma, Inc. 17
Gilead Sciences, Inc. 18
Italfarmaco S.p.A. 19
Karus Therapeutics Limited 20
miRagen Therapeutics, Inc. 21
Nerviano Medical Sciences S.r.l. 22
Novartis AG 23
PharmaEssentia Corporation 24
Teva Pharmaceutical Industries Ltd. 25
Polycythemia Vera - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
anagrelide hydrochloride CR - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
arsenic trioxide - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
dasatinib - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Drug to Inhibit Ribonucleotide Reductase for Polycythemia Vera and Essential Thrombocythemia - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
givinostat - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
idelalisib - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
KA-1463 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
M-009 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
M-012 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
MGN-4893 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
momelotinib dihydrochloride - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
NMSP-113 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
peginterferon alfa-2a - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
ropeginterferon alfa-2b - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
sonidegib phosphate - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Polycythemia Vera - Dormant Projects 76
Polycythemia Vera - Discontinued Products 77
Polycythemia Vera - Product Development Milestones 78
Featured News & Press Releases 78
May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012 78
May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases 78
Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition 79
Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition 80
Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera 81
Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 82
Oct 10, 2013: AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera 82
Dec 10, 2012: AOP Orphan Pharma Reports Positive Phase II Data Of New Mono-pegylated Interferon Alpha 2b For Treatment Of Polycythemia Vera 83
Feb 17, 2011: miRagen Therapeutics Receives Orphan Drug Designation for MGN-4893 for Treatment of Polycythemia Vera 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86

List of Tables

Number of Products under Development for Polycythemia Vera, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Polycythemia Vera - Pipeline by ANP Technologies, Inc., H2 2016 14
Polycythemia Vera - Pipeline by Bristol-Myers Squibb Company, H2 2016 15
Polycythemia Vera - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 16
Polycythemia Vera - Pipeline by Galena Biopharma, Inc., H2 2016 17
Polycythemia Vera - Pipeline by Gilead Sciences, Inc., H2 2016 18
Polycythemia Vera - Pipeline by Italfarmaco S.p.A., H2 2016 19
Polycythemia Vera - Pipeline by Karus Therapeutics Limited, H2 2016 20
Polycythemia Vera - Pipeline by miRagen Therapeutics, Inc., H2 2016 21
Polycythemia Vera - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016 22
Polycythemia Vera - Pipeline by Novartis AG, H2 2016 23
Polycythemia Vera - Pipeline by PharmaEssentia Corporation, H2 2016 24
Polycythemia Vera - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 32
Number of Products by Stage and Molecule Type, H2 2016 34
Polycythemia Vera - Dormant Projects, H2 2016 76
Polycythemia Vera - Discontinued Products, H2 2016 77